Stachydrine (hydrochloride)
(Synonyms: 盐酸水苏碱) 目录号 : GC13840A pyrrolidine betaine with anticancer and cardioprotective effects
Cas No.:4136-37-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Stachydrine is an anti-metastatic agent.
Stachydrine, a pyrrolidine betaine, was first isolated from seed husk and the pulp of the fruit of C. Leonurus, and many other Asian plants and fruits.
In vitro: The aim of a previous study was to investigate the effects of stachydrine (STA) on norepinephrine (NE) induced hypertrophy and the changes of calcium transients in neonatal rat cardiomyocytes. Results showed that NE treatment could increase protein synthesis, cell surface area, the expression level of β-MHC and β/α-MHC ratio and these effects were attenuated by STA treatment. In addition, NE-induced hypertrophy was associated with accelerated decay of Ca2+-transient, increased phospholamban expression, increased Ca2+-transient amplitude, hyper-phosphorylation, increased intracellular cAMP level, as well as PKA overactivation. All of these effects could be inhibited by STA treatment significantly [1].
In vivo: Previous study evaluated the effect of stachydrine on the expression of caspase-9 and 12 in rats with unilateral ureteral obstruction. Results showed that degree of renal interstitial fibrosis, serum creatinine, blood urea nitrogen, the renal tubular interstitial damage index, and expression of caspase-9 and 12 in the stachydrine-treatment groups were significantly decreased [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Zhang, C. ,Shan, X.-L.,Liao, Y.-L., et al. Effects of stachydrine on norepinephrine-induced neonatal rat cardiac myocytes hypertrophy and intracellular calcium transients. BMC Complement. Altern. Med. 14, 474 (2014).
[2] Zhang C, Lu Y, Zhou YJ, Tong QQ, Qu C, Kang TJ. The effect of stachydrine on the expression of caspase-12 in rats with unilateral ureteral obstruction. J Urol. 2014 Nov;192(5):1549-54.
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 5.5679 mL | 27.8396 mL | 55.6793 mL |
5 mM | 1.1136 mL | 5.5679 mL | 11.1359 mL |
10 mM | 0.5568 mL | 2.784 mL | 5.5679 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。